Summary

batflight86 Newbie

  • [Safety comparability associated with omalizumab along with glucocorticoid within rush allergen immunotherapy].
Offline Offline
Posts:
0 (0 per day)
Age:
N/A
Date Registered:
May 02, 2024, 05:26:06 PM
Local Time:
May 17, 2024, 09:51:24 PM
Last Active:
May 03, 2024, 05:08:05 AM
Signature:
746, p-value = Zero.001, CI = 3.339, A single.153] to predict alteration of HbA1c inside the final model [R2 = 3.549, p-value < 3.001] without any